Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1721-1728

  Satoh, Takashi ^a,b   Tanaka, Yoko ^a   Okazaki, Yuka ^a   Kaburaki, Junichi ^c   Ikeda, Yasuo ^d   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c Shin Akasaka Clinic   (Japan)

^d WASEDA UNIVERSITY   (Japan)

Author keywords

Autoantigens and autoantibodies; Haematopoietic; Immunological techniques; Laboratory diagnosis; Systemic lupus erythematosus and autoimmunity

Indexed keywords

HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN M; SEROTONIN;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCORING SYSTEM; SEROTONIN RELEASE; SLE DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PLATELET FACTOR 4; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA;

EID: 84865320907     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes145     Document Type: Article

References (32)

1. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:340S-80S.
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121: 535-55.
3. Matsuo T, Suzuki S, Matsuo M, Kobayasi H. Preexisting antibodies to platelet factor 4-heparin complexes in patients with acute coronary syndrome who have no history of heparin exposure. Pathophysiol Haemost Thromb 2005; 34:18-22.
4. Bennett-Guerrero E, Slaughter TF, White WD et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1567-72.
5. Martinuzzo ME, Forastiero RR, Adamczuk Y, Pombo G, Carreras LO. Antiplatelet factor 4-heparin antibodies in patients with antiphospholipid antibodies. Thromb Res 1999;95:271-9.
6. Martin-Toutain I, Piette JC, Diemert MC et al. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 2007;16: 79-83.
7. Alpert D, Mandl LA, Erkan D et al. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008;67: 395-401.
8. Pauzner R, Greinacher A, Selleng K et al. False positive tests for heparin induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009;7:1070-4.
9. de Larranaga G, Martinuzzo M, Bocassi A, Fressart MM, Forastiero R. Heparin-platelet factor 4 induced antibodies in patients with either autoimmune or alloimmune antiphospholipid antibodies. Thromb Haemost 2002;88: 371-3.
10. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
12. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
13. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
14. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med 2003;114:322-5.
15. Warkentin TE, Sheppard JA, Moore JC et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6.
16. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006;4:281-2.
17. Kuwana M, Medsger TA Jr, Wright TM. Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides. Clin Immunol Immunopathol 1995;76: 266-78.
18. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
19. Rauova L, Poncz M, McKenzie SE et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005;105: 131-8.
20. Li ZQ, Liu W, Park KS et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002;99:1230-6.
21. Izban KF, Lietz HW, Hoppensteadt DA et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl 1):51-6.
22. Bauer TL, Arepally G, Konkle BA et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6.
23. Amiral J, Pouplard C, Vissac AM et al. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000;109:336-41.
24. Untch B, Ahmad S, Jeske WP et al. Prevalence, isotype, and functionality of anti-heparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia: the pathogenic role of IgG. Thromb Res 2002;105:117-23.
25. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981;57:199-202.
26. Bourhim M, Darnige L, Legallais C et al. Anti-b2-glycoprotein 1 antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model. J Mol Recognit 2003;16:125-30.
27. Warkentin TE. Current agents for the treatment of patients with heparin-induced thrombocytopenia. Curr Opin Pulm Med 2002;8:405-12.
28. Matsuo T, Suzuki S, Matsuo M, Kobayasi H. Preexisting antibodies to platelet factor 4-heparin complexes in patients with acute coronary syndrome who have no history of heparin exposure. Pathophysiol Haemost Thromb 2005; 34:18-22.
29. Bennett-Guerrero E, Slaughter TF, White WD et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1567-72.
30. Kato S, Takahashi K, Ayabe K et al. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. Br J Haematol 2011;154:373-7.
31. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121:632-6.
32. Rauova L, Zhai L, Kowalska MA et al. Role of platelet surface PF4 antigenic complexes in heparininduced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006;107: 2346-53.